This month’s candidate, EnteroMedics (ETRM), has developed a unique approach to treating obesity, which affects up to 685 million people worldwide. The company’s proprietary VBLOCtherapy directly targets the body’s internal mechanism for regulating hunger and appetite. Current obesity treatments cannot compare to its record of safety and success. The EnteroMedics system is approved for use in Australia, and is currently in clinical trials in Europe and the U.S. Excellent fourth quarter results sparked heavy buying that pushed shares above 2.00, but my 12-month price target is 3.25. Open up your issue now and read all the details on EnteroMedics and all my current stock recommendations.
